NCT01620112

Brief Summary

The purpose of this study is to determine whether different clonidine concentration on axillary brachial plexus block with 1,5% lidocaine for upper limb surgery may influence the sensory and motor block onset time and duration, postoperative analgesia duration, postoperative pain intensity

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Feb 2009

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2009

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2011

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

June 9, 2012

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 15, 2012

Completed
Last Updated

June 15, 2012

Status Verified

June 1, 2012

Enrollment Period

2.4 years

First QC Date

June 9, 2012

Last Update Submit

June 14, 2012

Conditions

Keywords

brachial plexuslidocainealfa 2 adrenergic receptor clonidineorthopedic procedure

Outcome Measures

Primary Outcomes (1)

  • sensorial and motor block duration

    to compare two concentrations of clonidine on different volumes of lidocaine, in terms of sensorial and motor block duration

    24 hours after surgery

Secondary Outcomes (4)

  • adverse effects of additive clonidine on axillary brachial plexus block in upper limb surgery

    24 hours after surgery

  • postoperative analgesia duration

    24 hours

  • sensorial and motor block onset time

    24 hours

  • postoperative pain intensity

    24 hours

Study Arms (4)

low clonidine concentration

ACTIVE COMPARATOR

clonidine concentration 1 ml on 40 ml of lidocaine 1.5% for upper brachial plexus

Drug: low clonidine concentration

lidocaine 20 ml 1,5%

ACTIVE COMPARATOR

lidocaine 20 ml 1,5% without clonidine for axillary brachial plexus block for upper limb surgery

Drug: Lidocaine

high clonidine concentration

ACTIVE COMPARATOR

clonidine concentration 150 mcg on 20 ml of lidocaine 1,5% for upper brachial plexus

Drug: high Clonidine concentration

40 ml lidocaine 1,5%

ACTIVE COMPARATOR

40 ml of lidocaine 1,5% without clonidine for upper brachial plexus

Drug: Lidocaine 40 ml

Interventions

Clonidine 1 ml - 150 mcg on 20 ml de lidocaine 1,5% on axillary brachial plexus block for upper limb surgery

high clonidine concentration

Clonidine 1 ml - 150 mcg on 40 ml of lidocaine 1,5% - single injection on axillary brachial plexus block for upper limb

low clonidine concentration

Lidocaine 1,5% 20 ml 300 mg for single injection on axillary brachial plexus block for upper lim surgery

lidocaine 20 ml 1,5%

Lidocaine 40 ml 1,5% 600 mg single injection for axillary brachial plexus block for upper limb surgery

40 ml lidocaine 1,5%

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • both genders,
  • over 18 years old,
  • American Society of Anesthesiologists (ASA) 1 to 3

You may not qualify if:

  • patients with chronic use of analgesics and non-steroidal anti-inflammatories drugs,
  • pregnant,
  • with infection at the puncture site,
  • coagulopathies or intolerance to drugs used in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Bundle-Branch BlockMotor ActivityPain, Postoperative

Interventions

Lidocaine

Condition Hierarchy (Ancestors)

Heart BlockArrhythmias, CardiacHeart DiseasesCardiovascular DiseasesCardiac Conduction System DiseasePathologic ProcessesPathological Conditions, Signs and SymptomsBehaviorPostoperative ComplicationsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
CARE PROVIDER
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assad AR

Study Record Dates

First Submitted

June 9, 2012

First Posted

June 15, 2012

Study Start

February 1, 2009

Primary Completion

July 1, 2011

Study Completion

July 1, 2011

Last Updated

June 15, 2012

Record last verified: 2012-06